The investigational drug demonstrated robust STAT6 degradation in blood and skin that was well tolerated and safe in healthy volunteers.

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic ...

The committee concluded that dupilumab does not represent a cost-effective use of resources, so could not be recommended for treating severe asthma with type 2 inflammation.

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

Kymera Therapeutics Inc. (NASDAQ:KYMR) saw its stock jump 37.3% in premarket trading after the company announced strong Phase ...

Melanie Hilgers, a dermatologist in Luxembourg, treats many sufferers in her practice, in which she often sees a combination ...

Kymera Therapeutics (NASDAQ:KYMR) rose ~16% in after-hours trading Friday after the company announced it would release phase 1 data of its inflammatory diseases oral candidate KT-621 in healthy ...

Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

May 27, 2025 — A new study suggests that boys who become overweight in their early teens risk damaging the genes of their future children, increasing their chances of developing asthma ...

Asthma is the most common chronic disease of childhood and, in the latter part of the 20th century, reached epidemic proportions. Asthma is generally believed to result from gene-environment ...